drugset / Trial / NCT01681433
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Phase 2
Terminated
72 enrolled
Costantine Albany
Achieve Life Sciences · collabHoosier Cancer Research Network · collab
RandomizedCrossoverOpen-labelTreatment
Summary
This Phase II study has been designed to evaluate the anti-tumor effects of adding OGX-427 to continuing abiraterone acetate and prednisone treatment in men with metastatic castrate-resistant prostate cancer (MCRPC) who have prostate-specific antigen (PSA) progression
Timeline
- Start
- 2012-12
- Primary completion
- 2017-06-21
- Completion
- 2017-06-21
Publications
- Background Kim N. Chi, Christopher Sweeney, Cindy Jacobs, Patricia S. Stewart, Noah M. Hahn. The Pacific trial: A randomized phase II study of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC) and PSA progression while receiving abiraterone acetate (AA). J Clin Oncol 31, 2013 (suppl; abstr TPS5101) http://abstracts2.asco.org/AbstView_132_115104.html
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apatorsen | Antisense oligonucleotide | 800 mg | Intravenous |
| Background | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Background | Prednisone | Other / unclassified | 10 mg | Oral |
| Background | Prednisone | Other / unclassified | 20 mg | Oral |